26
|
Chiappa V, Murru G, Bogani G, Galiano V, Ditto A, Martinelli F, Vinti D, Raspagliesi F. Intraoperative ultrasound in the conservative treatment of borderline ovarian tumors. Australas J Ultrasound Med 2019. [DOI: 10.1002/ajum.12149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
27
|
Chiappa V, Bogani G, Raspagliesi F. Fusion imaging as a promising technique to locate uncertain PET‐CT capitation. Australas J Ultrasound Med 2019. [DOI: 10.1002/ajum.12148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
28
|
Chiappa V, Ceni V, Bogani G, Ditto A, Martinelli F, Murru G, Galiano V, Raspagliesi F. Sonographic appearance of Uterine Tumors Resembling Ovarian Sex Cord Tumors (UTROSCT). Australas J Ultrasound Med 2019. [DOI: 10.1002/ajum.12156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
|
29
|
Chiappa V, Fruscio R, Franchi D, Tartamella J, Raspagliesi F, Bogani G. Artificial intelligence (AI) weights the importance of factors predicting malignancy at the time of ultrasonographic (US) examination. Australas J Ultrasound Med 2019. [DOI: 10.1002/ajum.12142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Ledermann J, Shapira-Frommer R, Santin A, Lisyanskaya A, Pignata S, Vergote I, Raspagliesi F, Sonke G, Birrer M, Provencher D, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger P, Rudaitis V, Cristescu R, Kobie J, Ruman J, Matulonis U. Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.043] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Garralda E, van Hoef M, Ochsenreither S, Gianni L, Lorusso D, Fiedler W, Keilholz U, Klinghammer K, Dicke C, Kebenko M, Matos I, Tabernero J, Raspagliesi F, Del Conte G, Habel B, Baumeister H, Zurlo A. The GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.131] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
32
|
Fontanelli R, Stefanon B, Raspagliesi F, Kenda R, Tomasic G, Spatti G, Riboldi G, Di Donato P, Pilotti S, De Palo G. Adult Granulosa Cell Tumor of the Ovary: A Clinico Pathologic Study of 35 Cases. TUMORI JOURNAL 2018; 84:60-4. [PMID: 9619717 DOI: 10.1177/030089169808400113] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Aims and background Adult granulosa cell tumor has a low malignant potential but requires an extensive follow-up of more than 5 years to accurately assess tumor activity. The aim of the present study was to evaluate the clinical characteristics, the treatment and the outcome of this rare ovarian tumor. Study design A retrospective review of 35 cases treated at primary onset of disease during a 23-year period from 1971 to 1993. Results The disease-free survival rate for stages IA-B-C at 5 and 10 years was 90% and 84%, respectively; for stages III-IV the 5-year freedom from progression rate was 16%. Conclusions The most important prognostic factor appears to be the extent of tumor involvement outside of the ovary.
Collapse
|
33
|
Deraco M, Rossi CR, Pennacchioli E, Guadagni S, Somers DC, Santoro N, Raspagliesi F, Kusamura S, Vaglini M. Cytoreductive Surgery Followed by Intraperitoneal Hyperthermic Perfusion in the Treatment of Recurrent Epithelial Ovarian Cancer: A Phase II Clinical Study. TUMORI JOURNAL 2018; 87:120-6. [PMID: 11504363 DOI: 10.1177/030089160108700302] [Citation(s) in RCA: 67] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Aims and Background The optimal salvage therapy for recurrent ovarian carcinoma has not been clearly established. Response to second-line chemotherapy is low, with a short median survival (8.8-15 months). We investigated the effect of an aggressive approach consisting of surgery followed by intraperitoneal drug delivery and local hyperthermia. Patients and Methods In a phase II clinical study, 27 patients with advanced/recurrent ovarian carcinoma were treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Median patient age was 53 years (range, 30-67) and mean follow-up was 17.4 months (range, 0.3-36.0). Patients had been surgically staged and heavily pretreated with cisplatin-based, taxol-based or taxol/platinum-containing regimens. Nineteen (70%) patients were cytoreduced to minimal residual disease <2.5 mm. The intraperitoneal hyperthermic perfusion was performed with the closed abdomen technique, using a preheated polysaline perfusate containing cisplatin (25 mg/m2/L) + mitomycin C (3.3 mg/m2/L) through a heart-lung pump (mean flow of 700 mL/min) for 60 min in the hyperthermic phase (42.5 °C). Results Two-year overall survival was 55%. Median times to overall progression and local progression were 16 months and 21.8 months, respectively. Variables that affected the overall survival or time to progression were as follows: residual disease (P = 0.00025), patient age (P = 0.04), and lag time between diagnosis and cytoreductive surgery + intraperitoneal hyperthermic perfusion (P = 0.04). Treatment-related morbidity, mortality and acute toxicity (grade II-III) rates were 11%, 4% and 11%, respectively. Eight (89%) of 9 patients had ascites resolution. Conclusion Our results suggest that cytoreductive surgery + intraperitoneal hyperthermic perfusion is a well-tolerated, feasible and promising alternative in the management of selected patients with recurrent ovarian cancer, but further randomized controlled studies are needed in order to confirm our findings.
Collapse
|
34
|
Berra B, Rapelli S, Monticelli G, Fighetti MA, Della Mea I, Raspagliesi F, Di Re E, Ringhini R, Bombardieri E. Usefulness and Potential Pitfalls of Sialic Acid Determination in Sera of Patients with Ovarian Tumors. Int J Biol Markers 2018; 1:39-46. [PMID: 3693972 DOI: 10.1177/172460088600100107] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Increasing evidence in the literature indicates that serum sialic acid is increased in cancer patients suggesting a possible usefulness of its determination as a tumor marker. However there are many discrepancies in the data reported, probably due to methodological errors, mainly in lipid bound sialic measurement. In this paper we illustrate the results obtained when we applied a method worked out in our laboratory for the determination of total and fractionated sialic acid (lipid and protein bound) to the analysis of sera from patients with ovarian tumors and the preliminary data on the follow up of selected cases. The potential pitfalls in using this relatively new tumor marker will be critically evaluated.
Collapse
|
35
|
Oriana S, Raspagliesi F, Duca PG, Coradini D, Di Re EM, Ragazzi D, Grillo T, Luciani L. Changes in Receptor Status after Treatment with Tamoxifen in Endometrial Cancer. Int J Biol Markers 2018; 3:233-6. [PMID: 3235850 DOI: 10.1177/172460088800300403] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Estrogen (ER) and progesterone receptor (PgR) status was determined in 41 women with operable endometrial cancer before and after administration of tamoxifen (TAM). The first sample was obtained by hysteroscopy to ensure a precise biopsy of neoplastic tissue; the second was done on the surgical specimen. PgR content was significantly increased after TAM treatment and this data was compared with the degree of tumor differentiation.
Collapse
|
36
|
Grosso G, Raspagliesi F, Baiocchi G, Di Re E, Colavita M, Cobellis L. Endometrioid Carcinoma of the Ovary: A Retrospective Analysis of 106 Cases. TUMORI JOURNAL 2018; 84:552-7. [PMID: 9862515 DOI: 10.1177/030089169808400508] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Aims and background This report retrospectively analyzes 106 cases of endometrioid carcinoma of the ovary treated at the National Cancer Institute of Milan from 1974 through December 1993. In 12 of the 106 cases (11.3%) a synchronous carcinoma of the uterine body was observed. Methods and study design Only patients who had previously untreated disease were included in the study. Patients with synchronous tumors were staged according to their ovarian cancer and treated according to the stage of that disease. Results Thirty-nine patients (36.8%) had stage I, 17 (16.0%) stage II, 43 (40.6%) stage III, and 7 (6.6%) stage IV disease. Moderately plus poorly differentiated tumors were present in 76 of the 106 cases (71.7%). Considering the 67 patients with advanced disease, residual tumor was absent in 27 cases (40.3%), ≤ 2 cm in 17 (25.4%), and > 2 cm in 23 (34.3%) cases. Systematic pelvic and para-aortic lymphadenectomy was performed in 60 patients (56.6%); selective sampling was carried out in 23 cases (21.7%). After surgery, 77 patients underwent various chemotherapy regimens. Conclusion Using univariate analysis, FIGO stage, tumor grade, residual disease after surgery, lymph node status, and platinum in the chemotherapy regimen significantly influenced 5-year survival. However, when all these variables were included in a multivariate analysis only FIGO stage still had a significant impact on survival. Survival analysis also showed a trend towards longer survival in patients with synchronous tumors.
Collapse
|
37
|
Bogani G, Ditto A, Martinelli F, Signorelli M, Raspagliesi F, Lorusso D. Neoadjuvant chemotherapy-related leukopoenia as a biomarkers predicting survival outcomes in locally advanced cervical cancer. Eur J Surg Oncol 2018. [DOI: 10.1016/j.ejso.2018.01.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
38
|
Bergamini A, Ferrandina G, Candiani M, Cormio G, Giorda G, Lauria R, Perrone AM, Scarfone G, Breda E, Savarese A, Frigerio L, Gadducci A, Mascilini F, Maneschi F, Cassani C, Marchetti C, Cecere SC, Biglia N, De Giorgi U, Raspagliesi F, Lorusso D, Mangili G. Laparoscopic surgery in the treatment of stage I adult granulosa cells tumors of the ovary: Results from the MITO-9 study. Eur J Surg Oncol 2018; 44:766-770. [PMID: 29576462 DOI: 10.1016/j.ejso.2018.03.001] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2017] [Revised: 02/16/2018] [Accepted: 03/05/2018] [Indexed: 12/21/2022] Open
Abstract
OBJECTIVE Surgery represents the mainstay of treatment of stage I adult type granulosa cell tumors of the ovary (AGCTs). Because of the rarity and indolent course of the disease, no prospective trials are available. Open surgery has long been considered the traditional approach; oncological safety of laparoscopy is only supported by small series or case reports. The aim of this study was to compare the oncological outcomes between laparoscopic and open surgery in stage I AGCTs treated within the MITO (Multicenter Italian Trials in Ovarian cancer) Group. METHODS Data from patients with stage I AGCTs were retrospectively collected. Clinicopathological features were evaluated for association with relapse and death. Survival curves were calculated using the Kaplan-Meier method and compared with the log-rank test. The role of clinicopathological variables as prognostic factors for survival was evaluated using Cox's regression model. RESULTS 223 patients were identified. Stage 1A, 1B and 1C were 61.5%, 1.3% and 29.6% respectively. 7.6% were apparently stage I. Surgical approach was laparoscopic for 93 patients (41.7%) and open for 130 (58.3%). 5-years DFS was 84% and 82%, 10-years DFS was 68% and 64% for the laparoscopic and open-group (p = 0.6).5-years OS was 100% and 99%, 10 years OS was 98% and 97% for the laparoscopic and open-surgery group (p = 0.8). At multivariate analyses stage IC, incomplete staging, site of primary surgery retained significant prognostic value. CONCLUSION The present study suggests that surgical route does not affect the oncological safety of patients with stage I AGCTs, with comparable outcomes between laparoscopic and open approach.
Collapse
|
39
|
Leone Roberti Maggiore U, Chiappa V, Ferrero S, Bogani G, Perotto S, Martinelli F, Ditto A, Raspagliesi F. Subjective Ultrasound Assessment and the Adnex Model to Differentiate between Benign and Malignant Ovarian Tumors. J Minim Invasive Gynecol 2017. [DOI: 10.1016/j.jmig.2017.08.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
40
|
Martinelli F, Ditto A, Bogani G, Signorelli M, Chiappa V, Perotto S, Scaffa C, Recalcati D, Lorusso D, Raspagliesi F. Sentinel Node Detection in Endometrial Cancer: A Single Center Experience Over 200 Cases of Hysteroscopic Injection of Tracers. J Minim Invasive Gynecol 2017. [DOI: 10.1016/j.jmig.2017.08.170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
41
|
Bogani G, Martinelli F, Ditto A, Signorelli M, Chiappa V, Leone Roberti Maggiore U, Lorusso D, Raspagliesi F. Assessing the Risk of Pelvic and Para-Aortic Nodal Involvement in Apparent Early-Stage Ovarian Cancer Undergoing Retroperitoneal Staging. J Minim Invasive Gynecol 2017. [DOI: 10.1016/j.jmig.2017.08.169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
42
|
Bogani G, Maltese G, Morano F, Lorusso D, Ditto A, Signorelli M, Raspagliesi F. Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: a predictors- and nomogram-based analyses. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Lepori S, Fontanella C, Maltese G, Tripodi E, Martinelli F, Bogani G, Ditto A, Signorelli M, Scaffa C, Raspagliesi F, Lorusso D. Phase II study of the safety and efficacy of oral capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx429.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Signorelli M, Bogani G, Morano F, Maltese G, Ditto A, Raspagliesi F, Lorusso D. The impact of chemotherapy-related leukopenia on survival outcomes in locally advanced cervical cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx429.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Fontanella C, Barcellini A, Vitale M, Lepori S, Maltese G, Tripodi E, Cerrotta A, Martinelli F, Andreetta C, Bogani G, Ditto A, Signorelli M, Scaffa C, Sacco C, Raspagliesi F, Lorusso D. Is chemotherapy worthwhile in patients with high-risk, lymph node negative, FIGO stage 1, endometrial cancer? Ann Oncol 2017. [DOI: 10.1093/annonc/mdx429.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
46
|
Lepori S, Fontanella C, Maltese G, Tripodi E, Martinelli F, Bogani G, Ditto A, Signorelli M, Scaffa C, Raspagliesi F, Lorusso D. Phase II study of the safety and efficacy of oral capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx372.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Ledermann J, Sehouli J, Zurawski B, Raspagliesi F, De Giorgi U, Banerjee S, Arranz Arija J, Romeo Marin M, Lisyanskaya A, Póka R, Mihutiu S, Markowska J, Cebotaru C, Herraez AC, Colombo N, Kovalenko N, Kutarska E, Hall M, Belli R, Zurlo A. A double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.035] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Fontanella C, Lepori S, Barcellini A, Maltese G, Andreetta C, Tripodi E, Martinelli F, Cerrotta A, Bogani G, Ditto A, Signorelli M, Scaffa C, Sacco C, Raspagliesi F, Lorusso D. Is chemotherapy worthwhile in patients with FIGO stage 1B, lymph nodes negative, grade 3 endometrial cancer? Ann Oncol 2017. [DOI: 10.1093/annonc/mdx372.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
49
|
Bellati F, Papadia A, Gasparri ML, Scanagatta P, Carriero F, Beneditti Panici P, Raspagliesi F. Tertiary cytoreduction for recurrent endometrial cancer. EUR J GYNAECOL ONCOL 2017; 38:132-134. [PMID: 29767882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
This paper reviews the surgical approach experiences in endometrial cancer recurrence and presents for the first time data on the surgical management of endometrial cancer patients at the time of their second recurrence. Surgery could represent a pivotal role in selected cases of recurrent endometrial cancer, offering long-term complete remissions and a survival advantage.
Collapse
|
50
|
Martinelli F, Ditto A, Bogani G, Signorelli M, Chiappa V, Lorusso D, Raspagliesi F. Laparoscopic Mapping in Endometrial Cancer Following Hysteroscopic Injection of Indocyanine Green. J Minim Invasive Gynecol 2016. [DOI: 10.1016/j.jmig.2016.08.244] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|